OMDA

Does Omada Health, Inc. (OMDA) have what it takes to be a top stock pick for momentum investors? Let's find out.

Omada Health, Inc. (OMDA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Omada Health, Inc. (OMDA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

SAN FRANCISCO, May 27, 2026 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, today announced that members of senior management will participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026, taking place in Miami, including a fireside chat on Wednesday, June 10, at 8:20 a.m. PST. The webcast will be available online at https://investors.omadahealth.com/news-events/events.

Omada Health NASDAQ: OMDA reported what executives described as a “milestone quarter” for the first quarter of 2026, highlighting 42% year-over-year revenue growth, expanding margins, and positive adjusted EBITDA alongside a raised full-year outlook.

SAN FRANCISCO, May 07, 2026 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA) announced it will serve as an independent program administrator in Eli Lilly and Company's Employer Connect program. Omada will offer its GLP‑1 Care Track, including clinical evaluation, prescribing, and ongoing medication management, to employers.

SAN FRANCISCO, April 17, 2026 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual-first provider of between-visit care, announced new study results demonstrating that Omada members in its GLP-1 Care Track lost, on average, 1.8 times more total weight and reduced their body fat percentage twice as much as the comparison group.1 The Omada members also saw an increase in muscle mass percentage and improvements in other well-being measures.1 These findings suggest that Omada's program may optimize the weight loss results of GLP-1s,1 mitigating a key risk of muscle loss associated with GLP-1s.2 Research has shown that during gradual weight loss from lifestyle interventions and older weight loss medications, roughly one-fourth of total weight loss is expected to come from lean mass.3 Popular GLP‑1 medications, such as semaglutide and tirzepatide, typically produce more rapid and substantial weight loss, which is often associated with a higher proportion of lean mass loss.2 One study found that on average, lean mass accounted for around 40% of the weight people lost.4 Omada's 12-week study followed 245 adults with obesity (BMI ≥30), including 151 Omada members and 94 control participants, all of whom had recently started a GLP-1 for weight management.1 It compared a group that was given access to Omada's GLP-1 Care Track–designed as a wraparound program to promote strength training and physical activity with one-on-one support to protect muscle mass and improve overall body composition–to a group that did not receive access to Omada. Both groups used an at-home scale to track weight and body composition and completed surveys to assess emotional health, well-being, self-efficacy, and physical function.

SAN FRANCISCO, April 16, 2026 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, today announced that it will release its first quarter 2026 results on Thursday, May 7, 2026, after market close, and host a conference call to review the results at 4:30 pm ET the same day. Conference Call Details A live audio webcast of the call will be available online at https://investors.omadahealth.com.